# Pulmonology (sarcoidosis) Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Mahalia Jackson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML035-SYN-TD
- Date: 1964-02-23
- Fictional facility: St. Posthumous Health Center
- Fictional author: Kwabena Asante-Miller, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Requested by: Beatrice Fontenot, MD

## Reason for consultation

Suspected sarcoidosis in a 52-year-old gospel singer with three months of exertional breathlessness, dry cough, tiredness and chest tightness, bilateral hilar lymphadenopathy with upper-zone reticulonodular opacities on today's chest radiograph, a calcium of 10.8 mg/dL, lymphopenia, and palpitations with first-degree atrioventricular block and frequent ventricular ectopy on ECG. Granulomas were reported at an abdominal operation twelve years ago; no pathology report is available. Please see her within two weeks, obtain tissue, and advise on cardiac evaluation and treatment. **S**

## History

Ms. Jackson, 52, is seen at the request of Dr. Fontenot two weeks after she presented with three months of exertional breathlessness, dry cough, tiredness and palpitations. A CT of the chest two days later showed symmetric hilar and mediastinal adenopathy with perilymphatic upper-lobe nodules, and I performed EBUS-guided needle aspiration five days ago. She had a hysterectomy at 40, when granulomas were reported in her abdomen; no report survives. She stopped her calcium and vitamin D tablet two weeks ago. She has had one more spell of palpitations while singing; no fainting. She has postponed three weeks of concerts. She has no eye symptoms and no rash. Never smoker; no relevant exposures. **S**

## Examination

| System | Finding |
|---|---|
| General | Well; weight 91.6 kg; blood pressure 126/78, pulse 82 and irregular with ectopic beats; oxygen saturation 95 percent on room air |
| Respiratory | Clear to auscultation; no crackles or clubbing |
| Cardiovascular | Occasional ectopic beats; no murmur; no ankle swelling |
| Skin | No erythema nodosum, lupus pernio, plaques or scar infiltration |

BP 126/78 mmHg; pulse 82 bpm; respirations 18/min; temperature 36.7 °C; oxygen saturation 95% on room air; weight 91.6 kg; BMI 31.7 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Fontenot's intake note and results. Chest radiograph: bilateral hilar adenopathy with upper-zone reticulonodular opacities (Scadding stage II). High-resolution CT: hilar, subcarinal and right paratracheal nodes up to 2.4 cm with fine calcification; perilymphatic micronodules in both upper lobes; no fibrosis. EBUS-guided aspiration of stations 4R, 7 and 11L: non-necrotizing granulomas; acid-fast and fungal stains negative; cultures pending; lavage lymphocytes 32 percent with a CD4 to CD8 ratio of 5.2. Interferon-gamma release assay and HIV negative. ECG: sinus rhythm, PR 240 ms, frequent unifocal ventricular ectopy. Pulmonary function today: FVC 74 percent, FEV1 76 percent, FEV1/FVC 80 percent, total lung capacity 78 percent, DLCO 62 percent of predicted. Calcium 10.7 mg/dL today off the supplement (10.8 at the first visit); creatinine 1.04 mg/dL; 25-hydroxyvitamin D 22 ng/mL; 1,25-dihydroxyvitamin D 84 pg/mL; alkaline phosphatase 128 U/L; lymphocytes 0.9; NT-proBNP 210 pg/mL. FVC percent predicted: 74% (low); FEV1 percent predicted: 76% (low); FEV1/FVC ratio: 80%; DLCO percent predicted: 62% (low); Calcium: 10.7 mg/dL (high); Creatinine: 1.04 mg/dL; eGFR (CKD-EPI 1959): 65 mL/min/1.73 m²; PHQ-9: 6. All results are synthetic.

## Assessment

1. **Pulmonary sarcoidosis with lymph node involvement** (D86.2). Sarcoidosis is confirmed to the standard the ATS guideline asks: a compatible clinical and radiologic picture, non-necrotizing granulomas in lymph nodes obtained by EBUS rather than mediastinoscopy, and no evidence so far of tuberculosis, fungal infection or lymphoma, with final cultures to follow. The lavage lymphocytosis with a high CD4 to CD8 ratio supports it. It is Scadding stage II, with mild restriction and a reduced DLCO, and she is symptomatic. The granulomas reported at her abdominal operation are consistent with long-standing disease. Sarcoidosis is more common in Black women in the United States and carries a higher risk of severe and fatal disease, so a complete organ screen matters. Serum ACE adds nothing to the diagnosis and is not needed. **S**
2. **Hypercalcemia** (E83.52). Granulomas convert vitamin D to its active form, as the high 1,25-dihydroxyvitamin D with a low 25-hydroxyvitamin D shows. The supplement made it worse. No calcium or vitamin D supplements until the calcium is normal on treatment; then vitamin D may be replaced cautiously with calcium checks. Bone protection on glucocorticoids should use a bisphosphonate, not calcium tablets. **S**
3. **Palpitations with first-degree atrioventricular block and ventricular ectopy** (R00.2). Unexplained conduction disease and ventricular ectopy in a patient with proven extracardiac sarcoidosis means cardiac sarcoidosis must be excluded. The HRS consensus and the AHA statement advise Holter monitoring, an echocardiogram, cardiac MRI with late gadolinium enhancement and cardiac FDG-PET. The PET must be done before any glucocorticoid, which would mask active inflammation, and needs a 72-hour high-fat, very-low-carbohydrate preparation. **S**

## Recommendations

1. Complete the screen for other organ involvement: ophthalmology examination now and yearly; calcium, creatinine and liver tests at each visit; the ECG is done.
2. Cardiac evaluation within two weeks and before any treatment: 24-hour Holter, echocardiogram, cardiac MRI with late gadolinium enhancement, and cardiac FDG-PET with dietary preparation; joint review with cardiology.
3. If cardiac sarcoidosis is confirmed: prednisone 40 mg daily for about two months, then a slow taper over about six months toward 5 to 10 mg, with methotrexate 15 mg weekly rising to 20 mg and folic acid, continued for at least a year; if the heart is not involved, the same steroid-sparing approach for symptomatic stage II disease with impaired lung function, at a lower prednisone dose.
4. If cardiac sarcoidosis is confirmed with an ejection fraction above 35 percent, an electrophysiology study, and a dual-chamber defibrillator if sustained ventricular tachycardia is induced, given the conduction disease; a beta-blocker for the ventricular ectopy.
5. Before immunosuppression: hepatitis B and C serology (drawn today), tuberculosis already excluded by the interferon-gamma release assay, and PCV20, recombinant zoster and, if non-immune, hepatitis B vaccines; no live vaccines on treatment.
6. On treatment: pneumocystis prophylaxis with atovaquone while prednisone is 20 mg or more with methotrexate, avoiding trimethoprim-sulfamethoxazole; a bone density scan and a bisphosphonate; glucose, blood pressure, weight, sleep and mood checks; methotrexate blood tests every two to four weeks for three months, then every eight to twelve weeks; no alcohol.
7. Response assessment: lung function about two months after starting and then every three to six months; repeat cardiac FDG-PET three to six months into treatment.
8. Performing and travel: postpone concerts until the cardiac tests and any device implant are done, then resume a lighter schedule with rest days; voice care; carry a medicine list and any device card when travelling.

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Communication

Discussed with Dr. Fontenot the same day and with cardiology. The diagnosis and the reasons for testing her heart before starting prednisone were explained to Ms. Jackson, who agreed to the plan and to postponing her concerts for now. She decides who else receives this note. **S**

## Follow-up

Holter tomorrow; echocardiogram, eye examination, cardiac MRI and FDG-PET within two weeks; joint review with Dr. Fontenot and cardiology in two weeks to decide treatment; pulmonology review with lung function about two months after treatment starts. **S**

## Guideline basis

- Crouser ED, et al. Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2020;201(8):e26-e51 (PMID 32293205) (2020), American Thoracic Society
- Baughman RP, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J 2021;58(6):2004079 (PMID 34140301) (2021), European Respiratory Society
- Birnie DH, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014;11(7):1305-1323 (PMID 24819193) (2014), Heart Rhythm Society
- Cheng RK, et al. Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association. Circulation 2024;149(21):e1197-e1216 (PMID 38634276) (2024), American Heart Association
- Humphrey MB, et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol 2023;75(12):2088-2102 (PMID 37845798) (2022), American College of Rheumatology
- Singh JA, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64(5):625-639 (PMID 22473917) (methotrexate laboratory monitoring) (2012), American College of Rheumatology
- Baughman RP, et al. Sarcoidosis in America. Analysis Based on Health Care Use. Ann Am Thorac Soc 2016;13(8):1244-1252 (PMID 27509154) (2016), Annals of the American Thoracic Society
- Mirsaeidi M, et al. Racial difference in sarcoidosis mortality in the United States. Chest 2015;147(2):438-449 (PMID 25188873) (2015), CHEST
- Adult Immunization Schedule by Medical Condition and Other Indication (2026), Centers for Disease Control and Prevention
